NAMUR, Belgium, Sept. 7, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing diagnostic tests for cancer, today announced that its Chief Executive Officer, Cameron Reynolds, and its Vice President of Investor Relations, Scott Powell, are scheduled to attend and present at several conferences in September.
During their presentations, Mr. Reynolds and Mr. Powell will outline Volition's business, clinical, regulatory and operational milestones, as well as the Company's recently announced European commercialization strategy for its Nu.Q blood-based tests for colorectal cancer.
Details of the conferences are as follows:
|
Conference: |
2016 Wells Fargo Healthcare Conference |
|
Date: |
Thursday, September 8, 2016 |
|
Location: |
The Westin Boston Waterfront, Boston |
|
Conference: |
Rodman & Renshaw 18th Annual Global Investment Conference |
|
Date: |
Monday, September 12, 2016 |
|
Time: |
12:05 p.m. EDT |
|
Location: |
Lotte New York Palace Hotel, New York City |
|
Conference: |
17th Annual GCFF Toronto Conference 2016 |
|
Date: |
Saturday, September 17, 2016 |
|
Time: |
10:45 a.m. EDT |
|
Location: |
Courtyard Toronto Northeast/Markham, Markham, ON |
|
Conference: |
2016 Aegis Growth Conference |
|
Date: |
Wednesday, September 21, 2016 |
|
Time: |
1:00 p.m. PDT |
|
Location: |
The Encore at Wynn, Las Vegas |
|
Conference: |
MicroCap Leadership Summit |
|
Date: |
Friday, September 23, 2016 |
|
Time: |
8:30 a.m.-4:00 p.m. CDT (Small Group Presentations) |
|
Location: |
Westin Chicago Northwest Hotel, Itasca, IL |
Persons attending the conferences who would like to schedule a 1-on-1 meeting with Volition management during the conference may do so by contacting Tirth Patel of Edison Advisors at tpatel@edisongroup.com or Scott Powell, Vice President of Investor Relations of Volition, at S.Powell@volitionrx.com.
About Volition
Volition is a life sciences company focused on developing diagnostic tests for cancer. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.
Volition's goal is to make the tests as easy and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. Volition's research and development activities are currently centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.
Visit Volition's website (http://www.volitionrx.com) or connect with us via Twitter, LinkedIn, Facebook or YouTube.
|
Media / Investor Contacts |
|
|
Louise Day, Volition |
Scott Powell, Volition |
|
+44 (0)7557 774 620 |
+1 (646) 650-1351 |
|
Tirth Patel, Edison Advisors |
Katherine Fennell, Edison Advisors |
|
+1 (646) 653-7035 |
+44 (0) 20 7841 1556 |
Nucleosomics®, NuQ® and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
SOURCE VolitionRx Ltd